Overall, these analyses, which are consistent with our transcriptomic data, strongly suggest that IFN-mediated inflammation, which is associated with PRL and chronic neuroinflammation, persists even in the setting of a treatment that nearly completely abolishes new inflammatory lesions and relapses in MS but has only limited impact on clinical progression. The gene discussed is PRL; the disease is myeloid sarcoma.